375
Participants
Start Date
May 14, 2019
Primary Completion Date
December 31, 2028
Study Completion Date
June 30, 2032
IMA203 Product
The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
IMA203 product- flat dose
The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells
IMA203CD8 Product
The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
Nivolumab
Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.
IMADetect®
IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.
RECRUITING
Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie, Berlin
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
University of Pennsylvania, Perelamn Center for Advanced Medicine, Philadelphia
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
Universitätsklinikum Hamburg-Eppendorf, Hamburg
RECRUITING
University of Miami Hospital and Clinics, Miami
RECRUITING
Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
RECRUITING
Universitätsklinikum Bonn - Medizinische Klinik III, Bonn
RECRUITING
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz
RECRUITING
Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Klinikum rechts der Isar der Technischen Universität München, Munich
RECRUITING
Universitätsklinikum Würzburg, Würzburg
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Universitätsklinikum C.-G.-Carus Dresden, Dresden
Immatics US, Inc.
INDUSTRY